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Abstract
Background: Individual patient meta-analysis to determine the analgesic efficacy and adverse
effects of single-dose rofecoxib in primary dysmenorrhoea.
Methods:  Individual patient information was available from three randomised, double blind,
placebo and active controlled trials of rofecoxib. Data were combined through meta-analysis.
Number-needed-to-treat (NNT) for at least 50% pain relief and the proportion of patients who
had taken rescue medication over 12 hours were calculated. Information was collected on adverse
effects.
Results: For single-dose rofecoxib 50 mg compared with placebo, the NNTs (with 95% CI) for at
least 50% pain relief were 3.2 (2.4 to 4.5) at six, 3.1 (2.4 to 9.0) at eight, and 3.7 (2.8 to 5.6) at 12
hours. For naproxen sodium 550 mg they were 3.1 (2.4 to 4.4) at six, 3.0 (2.3 to 4.2) at eight, and
3.8 (2.7 to 6.1) at 12 hours. The proportion of patients who needed rescue medication within 12
hours was 27% with rofecoxib 50 mg, 29% with naproxen sodium 550 mg, and 50% with placebo.
In the single-dose trial, the proportion of patients reporting any adverse effect was 8% (4/49) with
rofecoxib 50 mg, 12% (6/49) with ibuprofen 400 mg, and 6% (3/49) with placebo. In the other two
multiple dose trials, the proportion of patients reporting any adverse effect was 23% (42/179) with
rofecoxib 50 mg, 24% (45/181) with naproxen sodium 550 mg, and 18% (33/178) with placebo.
Conclusions: Single dose rofecoxib 50 mg provided similar pain relief to naproxen sodium 550
mg over 12 hours. The duration of analgesia with rofecoxib 50 mg was similar to that of naproxen
sodium 550 mg. Adverse effects were uncommon suggesting safety in short-term use of rofecoxib
and naproxen sodium. Future research should include restriction on daily life and absence from
work or school as outcomes.
Background
Dysmenorrhoea is associated with painful cramping of
the lower abdominal or back muscles, with or without
other symptoms such as nausea, vomiting, and diarrhoea.
Onset of dysmenorrhoea is common during adolescence,
and up to 50% of women of reproductive age may be
affected [1], and 10% incapacitated for up to three days
each menstrual cycle. The pain caused by dysmenorrhoea
can be debilitating, resulting in women being unable to
perform daily activities, and being absent from work or
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school. In consequence, dysmenorrhoea is associated
with emotional, social, and economic burdens. Despite
the impact of dysmenorrhoea on daily living, few women
seek medical advice [2], or know which treatments work
[3].
Raised concentrations of uterine prostaglandins are
thought to cause the pain and cramping associated with
dysmenorrhoea [4-6]. Nonsteroidal anti-inflammatory
drugs (NSAIDs) inhibit prostaglandin synthesis and are
commonly used to treat the condition. The newer Cox-2
selective inhibitors (coxibs) also inhibit prostaglandin
synthesis, providing an alternative to conventional
NSAIDs. Relatively low rates of gastrointestinal adverse
effects allow the use of higher doses of coxibs in acute
pain and dysmenorrhoea. These high doses may have the
additional advantage of longer duration analgesia with
extended dosing intervals.
Systematic reviews have shown NSAIDs to be effective in
the treatment of primary dysmenorrhoea [7,8] While the
latest, Cochrane, review [8] reported on 4,066 women in
trials of NSAIDs in dysmenorrhoea, the trials themselves
were small, with an average of about 50 women per trial.
These 63 randomised double-blind trials investigated 21
different NSAIDS, at different doses, in studies of varying
design, varying outcomes, and varying duration.
At least moderate pain relief over a cycle was reported in
14 comparisons between NSAID (any NSAID, any dose)
and placebo in 599 women, with an NNT of 2.1 (1.9 to
2.5). The most studied NSAID was naproxen, with 287
women in seven trials, with an NNT of 2.5 (2.0 to 3.3) for
this outcome. An earlier review [7] included more trials,
some not double-blind, but came to substantially the
same conclusion about analgesic efficacy in primary dys-
menorrhoea. NSAIDs also improved activities of daily liv-
ing, though reported in only 216 women [8]. Adverse
event information in these trials was not informative
given the small number of women and trials, and that
adverse events were rare in younger women taking
NSAIDs for limited time.
Cox-2 selective inhibitors (coxibs) provide an alternative
to conventional NSAIDs, with a potential advantage of
once daily dosing [9-11]. This individual patient data
meta-analysis of rofecoxib in dysmenorrhoea aimed to
determine the efficacy and duration of analgesic activity of
single dose rofecoxib, and to evaluate adverse effects.
Methods
QUOROM guidelines [12] for quality of reporting of
meta-analyses were followed though no flow chart was
used since trial data all came from a single source.
Merck Research Laboratories, Rahway, New Jersey pro-
vided individual patient data from three Phase III trials of
rofecoxib in dysmenorrhoea (studies 38, 55 and 56), with
the guarantee that all relevant studies completed by July
2002 had been made available. One of the trials has been
published in full [9]. Searching PubMed to January 2004
identified one other randomised but open trial of
rofecoxib [13] not sponsored by Merck. For inclusion, tri-
als had to be randomised and double blind, compare
rofecoxib with placebo, and provide single dose efficacy
information. Outcome data were available for pain relief,
pain intensity, time to remedication (use of rescue analge-
sic), and adverse effects. Each trial report was independ-
ently read and scored for quality using a three item, 0–5
point scale [14]. For inclusion a trial had to score a mini-
mum of two points, one each for randomisation and dou-
ble blinding, out of a maximum of 5. A sixteen-point scale
was also used to assess trial validity [15].
Our intention was to use two pain outcomes (pain relief
over the first dose, and pain relief over the whole cycle)
with the outcome being that closest to at least half pain
relief. Over the first dose, this might be a measure of total
pain relief (TOTPAR), while over a whole cycle it may be
a patient global evaluation of good or excellent, rather
than mild, fair, no improvement, or worse. Analyses for
comparator treatments were based on information availa-
ble only from the trials of rofecoxib in this report. Out-
come data were pooled in an intention to treat (number
of patients randomised) analysis. Neither heterogeneity
tests nor funnel plots were used [16,17]. Instead clinical
homogeneity of trials was examined graphically [18].
Relative benefit (or risk) was calculated using a fixed
effects model [19] with no statistically significant differ-
ence between treatments assumed when the 95% confi-
dence intervals included 1. Number-needed-to-treat (or
harm) was calculated using the method of Cook and Sack-
ett [20] using pooled observations. NNT is the reciprocal
of the absolute risk reduction or increase; for instance, if
75 out of 100 patients benefit with treatment and only 25
out of 100 benefit with placebo, the absolute risk increase
is 0.75–0.25 = 0.5, and the NNT is 1/0.5 = 2. The z test
[21] was used to determine statistical differences between
NNTs for different doses, treatments or outcomes. Mean
adverse event rates were calculated, weighting by treat-
ment group size. Use of rescue medication was analysed as
the proportion of patients remedicating at different time
points within 12 hours.
Results
The mean age of women in the trials was 31 years, and at
baseline pain was moderate in 66% of women and severe
in 34%. All trials were randomised, double blind, and
compared oral doses of rofecoxib with an active controlBMC Women's Health 2004, 4:5 http://www.biomedcentral.com/1472-6874/4/5
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and placebo in women with moderate to severe pain due
to dysmenorrhoea. One trial was a single dose crossover
(study 38), and two were multiple dose crossovers (stud-
ies 55 and 56), where the crossover was between single
doses in different menstrual cycles. Single dose efficacy
data were available for the first 12 hours of treatment in
all trials, but not summary estimates over a cycle. Study
designs and quality and validity scores are shown in Table
1. All trials scored the maximum five points for quality
and at least 13/16 points for trial validity; some of the cri-
teria for validity were not appropriate because of the indi-
vidual patient presentation of results.
The single dose trial (study 38) was conducted over three
cycles. Each of 49 women received three of four treat-
ments (rofecoxib 25 mg, rofecoxib 50 mg, ibuprofen 400
mg, or placebo). For the two multiple dose studies, one
(study 55) compared a single dose of rofecoxib 50 mg fol-
lowed by 25 mg daily as required, naproxen sodium 550
mg every 12 hours, or placebo in 60 women over three
menstrual cycles. The other (study 56) compared
rofecoxib 50 mg as required, rofecoxib 50 mg followed by
25 mg daily as required, naproxen sodium 550 mg every
12 hours, or placebo in 122 women over four menstrual
cycles. Both trials reported multiple dose adverse effects.
In the multiple dose trials, all women received each treat-
ment regimen for one cycle.
Pain intensity and pain relief were measured using the
standard 4-point categorical pain intensity scale (0 none,
1 mild, 2 moderate, 3 severe) and a 5-point point pain
relief scale (0 none, 1 a little, 2 some, 3 a lot, 4 complete).
Pain measurements were collected using patient diaries.
Patients were assessed at baseline, then at least hourly for
eight hours, and again at 12 hours for single dose efficacy
data. The exact time at which a patient requested remedi-
cation (or rescue analgesic), if required, was recorded.
Adverse effects were recorded as the number of patients
with any adverse effect(s), or particular adverse effects.
Efficacy
Full efficacy results over six, eight and 12 hours are shown
in Table 2. All active treatments were significantly more
effective than placebo at all time points.
Rofecoxib 25 mg was tested in a single trial, rofecoxib 50
mg in three, ibuprofen 400 mg in one and naproxen
sodium 550 mg in two. For all the active analgesics the
proportion of patients with at least 50% pain relief was
about 60% at all time points, and with placebo it was
about 30% at all time points (Table 2). Numbers needed
to treat tended to be much the same for rofecoxib 50 mg,
ibuprofen 400 mg and naproxen sodium 550 mg, though
somewhat higher (worse) for rofecoxib 25 mg (Table 2).
There was no significant difference between NNTs for sin-
gle doses of study treatments at six, eight or 12 hours. For
instance, no significant difference at the 12 hour compar-
ison was seen between the NNTs of rofecoxib 25 mg and
rofecoxib 50 mg (z score 1.19, p = 0.23), ibuprofen 400
mg (z score 0.28, p = 0.78), or naproxen sodium 550 mg(z
score 1.09, p = 0.28), or between NNTs of rofecoxib 50 mg
and ibuprofen 400 mg (z score 0.26, p = 0.79), or
naproxen sodium 550 mg (z score 0.096, p = 0.60).
Remedication
The proportion of patients who remedicated at different
time points over 12 hours is shown in Figure 1. At 12
hours remedication occurred with 29% on rofecoxib 25
mg, 28% on rofecoxib 50 mg, 29% on naproxen sodium
550 mg, 41% on ibuprofen 400 mg, and 50% with
placebo.
Table 1: Trial details
Trial ID Study drug and dose, number of 
women
Design Observations after 8 
hrs
Quality 
score
Validity 
score
38 49 women
Rofecoxib 25 mg
Rofecoxib 50 mg
Ibuprofen 400 mg
Placebo
Single oral dose, parallel 3 menstrual 
cycles
12, 24 5/5 ≥13/16
55 60 women
Rofecoxib 50 mg then 25 mg as required
Naproxen sodium 550 mg every 12 hrs
Placebo
Oral. Multiple dose study with single 
dose efficacy data, multiple dose 
adverse events Cross-over, 1 of 6 
drug sequences 3 menstrual cycles
12 hour obervations after 
a single dose in a three-
day study
5/5 ≥13/16
56 122 women
Rofecoxib 50 mg as required
Rofecoxib 50 mg then 25 mg as required
Naproxen sodium 550 mg every 12 hrs
Placebo
Oral. Multiple dose study with single 
dose efficacy data, multiple dose 
adverse events Cross-over, 1 of 4 
drug sequences 4 menstrual cycles
12 hour obervations after 
a single dose in a three-
day study
5/5 ≥13/16BMC Women's Health 2004, 4:5 http://www.biomedcentral.com/1472-6874/4/5
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Remedication time for all drugs Figure 1
Remedication time for all drugs
Table 2: Number needed to treat for at least 50% pain relief
Improved with % improved
Number of 
trials
Drug and 
dose (mg)
Active Placebo Active Placebo Relative risk 
(95% CI)
NNT         
(95% CI)
Six hour ourcomes
1 Rofecoxib 25 66/115 45/118 57 38 1.5 (1.1 to 2.0) 5.0 (3.7 to 7.8)
3 Rofecoxib 50 140/226 70/225 62 31 2.0 (1.6 to 2.5) 3.2 (2.4 to 4.5)
1 Ibuprofen 400 31/49 10/47 63 21 3.0 (1.7 to 5.4) 2.4 (1.7 to 4.2)
2 Naproxen 
sodium 550
120/181 60/178 66 34 2.0 (1.6 to 2.5) 3.1 (2.4 to 4.4)
Eight hour ourcomes
1 Rofecoxib 25 70/115 44/118 61 37 1.6 (1.2 to 2.2) 4.2 (2.8 to 9.0)
3 Rofecoxib 50 147/226 73/225 65 32 2.0 (1.6 to 2.5) 3.1 (2.4 to 9.0)
1 Ibuprofen 400 30/47 11/47 61 21 2.6 (1.5 to 4.6) 2.6 (1.8 to 5.1)
2 Naproxen 
sodium 550
121/181 62/178 68 35 2.0 (1.6 to 2.4) 3.0 (2.3 to 4.3)
Twelve hour ourcomes
1 Rofecoxib 25 64/115 45/118 56 38 1.5 (1.1 to 1.9) 5.7 (3.3 to 20)
3 Rofecoxib 50 135/226 74/225 60 33 1.8 (1.5 to 2.3) 3.7 (2.8 to 5.6)
1 Ibuprofen 400 27/49 12/47 55 26 2.2 (1.3 to 3.7) 3.4 (2.1 to 9.2)
2 Naproxen 
sodium 550
111/181 62/178 61 35 1.8 (1.4 to 2.2) 3.8 (2.7 to 6.1)
68 1 2
0
10
20
30
40
50
Percent remedicating
Hours after dose
Rofecoxib 25 mg
Rofecoxib 50 mg
Ibuprofen 400 mg
Naproxen sodium 550 mg
PlaceboBMC Women's Health 2004, 4:5 http://www.biomedcentral.com/1472-6874/4/5
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Adverse effects
Few adverse effects of a particular type were reported, and
none were serious in any trial. The most commonly
reported adverse effects were nausea and somnolence, but
these occurred infrequently. A single dose in one trial
(study 38) gave the proportion of patients reporting any
adverse effect(s) as 10% (5/49 patients) with rofecoxib 25
mg, 8% (4/49) with rofecoxib 50 mg, 12% (6/49) with
ibuprofen 400 mg, and 6% (3/49) with placebo. With
multiple doses over a cycle, the proportion of patients
reporting any adverse effect(s) was 23% (42/179 patients)
with rofecoxib 50 mg, 24% (45/181) with naproxen
sodium 550 mg, and 18% (33/178) with placebo.
Discussion
Pain with dysmenorrhoea usually lasts for about three
days, though with considerable individual variation. Tri-
als of analgesics can have various forms. The simplest
might be to give the same analgesic for the whole of the
painful cycle, and ask a global question concerning effi-
cacy at the end. Women might then be crossed over to a
different treatment at the next cycle. A variation would be
to use the same basic structure, but make more detailed
evaluations of pain or pain relief over a limited time dur-
ing the first day, though a global question could always be
added. A more complicated design would use a cross-over
within a single cycle.
The three trials described here used a cross-over between
cycles, with detailed pain measurements over 12–24
hours in the first painful day. Twelve-hour and 24-hour
outcomes have also been reported in two other recent
studies of coxibs in dysmenorrhoea [10,11]. With previ-
ous NSAID studies [8] the outcome most often used in
placebo-controlled trials was at least moderate pain relief
or an equivalent outcome over a whole cycle. A recent
open-label study had a crossover design with drugs given
each successive day [13].
All three trials were of the highest reporting quality, and
had high validity scores, indicating that known sources of
bias are unlikely to occur [22,8]. We know that to be sure
of a result (as an NNT) we need information from about
400 patients when the NNT is about 2, but much more
when the NNT is higher (worse) [23]. Here we have infor-
mation from about 450 women with rofecoxib 50 mg and
360 with naproxen sodium 550 mg, but only about 200
women contributed for rofecoxib 25 mg and fewer than
100 for ibuprofen 400 mg (Table 2). For rofecoxib 25 mg
and ibuprofen 400 mg, therefore, uncertainty over the size
of the effect continues.
Individual patient information from three trials of high
quality showed that for the outcome of at least half pain
relief over 12 hours, rofecoxib, naproxen sodium and ibu-
profen were similarly effective in the treatment of pain
associated with dysmenorrhoea. This confirms what was
known from previous meta-analysis [8], in which most
information was for naproxen at various doses with an
NNT of 2.5 (2.0 to 3.3) for the outcome of at least moder-
ate pain relief over 3–5 days compared with placebo. In
this analysis the NNT for a single dose of 550 mg
naproxen sodium was between 3.0 and 3.8 over six to 12
hours. The Cochrane review had information on 287
women in seven placebo-controlled trials, while two of
the three trials here had information on 359 women tak-
ing naproxen sodium.
Rofecoxib 50 mg was statistically indistinguishable from
naproxen sodium 550 mg (Table 2) at all times, though
rofecoxib 25 mg tended to have numerically higher
(worse) NNTs at all times. Remedication over 12 hours
was statistically indistinguishable between rofecoxib
doses and naproxen. Here the number of women studied
was even larger, with 451 women involved in the trials
comparing rofecoxib 50 mg and placebo. The difference
between rofecoxib 50 mg and naproxen sodium 550 mg
would be in dosing schedules, with once versus twice a
day dosing.
Pain relief and duration of analgesia are not the only
issues of importance in dysmenorrhoea. The impact of
dysmenorrhoea on activities of daily living, disability or
function, and absence from work or school are additional
factors to be considered. These outcomes were not
addressed by the trials for rofecoxib, which were con-
ducted for regulatory purposes. This limits the utility of
the information, but trials of other coxibs (also conducted
for regulatory purposes) have also concentrated on pain
relief and duration of analgesia [10,11].
Future trials should examine a range of short-term analge-
sia and longer outcomes like interference with daily living
or absence from work or school. The analysis by Zhang
and colleagues [7] did examine these additional out-
comes, and found daily life to be less restricted with
naproxen or ibuprofen than with placebo, and fewer
absences from work or school to occur with naproxen
than with placebo. These outcomes are infrequently
reported [8], but are likely to be associated with pain, so
decreased pain should improve these other outcomes as
well. Verification of this assumption with data from high
quality clinical trials would be welcome, though.
Future individual patient analysis of trials in dysmenor-
rhoea would have the potential to examine issues around
the efficacy of analgesics in women with heavy menstrual
loss, or who use combined oral contraceptive pills. In this
analysis information was not available for these analyses,BMC Women's Health 2004, 4:5 http://www.biomedcentral.com/1472-6874/4/5
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and in any event any sub-groups would probably have
been too small for any definitive answer.
In the trials for rofecoxib, information on adverse effects
was collected using diaries. Few adverse effects were
reported to have occurred and none were serious. The
most common adverse effects were nausea and somno-
lence. These and headache have been frequently reported
with other coxibs [10,11] and NSAIDs [7,24]. The prob-
lem when interpreting information on adverse effects,
though, is that any symptom can be recorded as an
adverse event however tenuous its association to the study
drug. We cannot be certain whether these symptoms were
due to the condition or to the drug.
Conclusions
Based on information from three trials, a single dose of
rofecoxib 50 mg is as effective as a single dose of naproxen
sodium 500 mg in controlling the pain associated with
dysmenorrhoea, and causes relatively few adverse effects.
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